PT - JOURNAL ARTICLE AU - Ngo, Tran B. AU - Karkanitsa, Maria AU - Adusei, Kenneth M. AU - Graham, Lindsey A. AU - Ricotta, Emily E. AU - Darrah, Jenna R. AU - Blomberg, Richard D. AU - Spathies, Jacquelyn AU - Pauly, Kyle J. AU - Klumpp-Thomas, Carleen AU - Travers, Jameson AU - Mehalko, Jennifer AU - Drew, Matthew AU - Hall, Matthew D AU - Memoli, Matthew J AU - Esposito, Dominic AU - Kozar, Rosemary A. AU - Griggs, Christopher AU - Cunningham, Kyle W. AU - Schulman, Carl I. AU - Crandall, Marie AU - Neavyn, Mark AU - Dorfman, Jon D. AU - Lai, Jeffrey T. AU - Whitehill, Jennifer M. AU - Babu, Kavita M. AU - Mohr, Nicholas M. AU - Van Heukelom, Jon AU - Fell, James C. AU - Rooke, Whit AU - Kalish, Heather AU - Thomas, F. Dennis AU - Sadtler, Kaitlyn TI - SARS-CoV-2 Seroprevalence and Drug Use in Trauma Patients from Six Sites in the United States AID - 10.1101/2021.08.10.21261849 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.10.21261849 4099 - http://medrxiv.org/content/early/2021/08/11/2021.08.10.21261849.short 4100 - http://medrxiv.org/content/early/2021/08/11/2021.08.10.21261849.full AB - In comparison to the general patient population, trauma patients show higher level detections of bloodborne infectious diseases, such as Hepatitis and Human Immunodeficiency Virus. In comparison to bloodborne pathogens, the prevalence of respiratory infections such as SARS-CoV-2 and how that relates with other variables, such as drug usage and trauma type, is currently unknown in trauma populations. Here, we evaluated SARS-CoV-2 seropositivity and antibody isotype profile in 2,542 trauma patients from six Level-1 trauma centers between April and October of 2020 during the first wave of the COVID-19 pandemic. We found that the seroprevalence in trauma victims 18-44 years old (9.79%, 95% confidence interval/CI: 8.33 11.47) was much higher in comparison to older patients (45-69 years old: 6.03%, 4.59-5.88; 70+ years old: 4.33%, 2.54 – 7.20). Black/African American (9.54%, 7.77 – 11.65) and Hispanic/Latino patients (14.95%, 11.80 – 18.75) also had higher seroprevalence in comparison, respectively, to White (5.72%, 4.62 7.05) and Non-Latino patients (6.55%, 5.57 – 7.69). More than half (55.54%) of those tested for drug toxicology had at least one drug present in their system. Those that tested positive for narcotics or sedatives had a significant negative correlation with seropositivity, while those on anti-depressants trended positive. These findings represent an important consideration for both the patients and first responders that treat trauma patients facing potential risk of respiratory infectious diseases like SARS-CoV-2.Competing Interest StatementKS and MJM have filed a provisional patent application for a custom reagent utilized in this study.Clinical TrialThis cross-sectional natural history study was completed utilizing discarded plasma or serum samples from individuals undergoing bloodwork for medical treatments and was not associated with a Clinical Trial.Funding StatementThis research was supported in part by the Intramural Research Program of the NIH, including the National Institute for Biomedical Imaging and Bioengineering, the National Institute of Allergy and Infectious Disease, and the National Center for Advancing Translational Sciences. This project has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health, under contract number HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Disclaimer: The NIH, its officers, and employees do not recommend or endorse any company, product, or service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with Good Clinical Practice, the principles of the Belmont Report and HHS regulations enumerated under 45 CFR 46. The Chesapeake/Advarra Institutional Review Board served as the central IRB for five sites, and the University of Florida Institutional Review Board served as the IRB of record for the Jacksonsville, FL site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request to the corresponding author after article publication.